BioSpace News Archive

Thermo Fisher Scientific today announced the Thermo Scientific Aquilos 2 Cryo-FIB, a DualBeam system dedicated to the preparation of thin, electron-transparent samples from biological specimens

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one abstract from a collaboration trial with MD Anderson Cancer Center (MD Anderson) and two abstracts from investigator-sponsored trials, will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando from December 7-10, 2019.

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conformité Européene) IVD Marks and availability of its CEE-Sure® Blood Collection Tube and CEE-Sure® Sample Collection Shipping Kit in Europe

Risch brings more than 30 years of experience in medical strategy leadership to clients across the globe.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will be participating in the 13th Annual Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 21 in New York City

$37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation.

Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics

Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or the “Company”), announced today that it will host a conference call to discuss operational and financial highlights from its third quarter 2019 on Monday, November 11, 2019 at 8:30 a.m. ET.